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ABSTRACT
Background: High diuretic doses in chronic heart failure (HF) are potentially deleterious. We assessed
the effect of dynamic furosemide dose on all-cause mortality among HF ambulatory patients.
Methods and Results: A cohort of 560 ambulatory patients from an outpatient clinic specialized in HF,
with median age 70 years, 67% male, and 89% with moderate-severely reduced ejection fraction, was ret-
rospectively followed for up to 5 years. Dynamic furosamide exposure was categorized as low (0–59 mg/
d), medium (60–119 mg/d), high (120–159 mg/d), and very high (≥160 mg/d). Extended Cox models were
used to estimate the association between time-varying diuretic dose and mortality. A dose-dependent crude
association between higher doses of furosemide and death (hazard ratio [HR] = 1.34, 95% confidence in-
terval (CI): 1.06–2.16; HR = 2.09, 95% CI: 1.54–2.84, for high and very high dose, respectively) was totally
explained by patients’ characteristics and disease severity indicators (adjusted HR = 0.94, 95% CI: 0.63–
1.38; HR = 1.10, 95% CI: 0.79–1.55, for high and very high dose, respectively).
Conclusion: In this context, higher doses of diuretic did not impair survival, but rather indicated greater
severity of the patient’s condition. (J Cardiac Fail 2017;23:589–593)
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Congestion is a key component of heart failure (HF) that
determines symptoms, hospital admissions, and mortality.1 Of
all drugs used in HF, diuretics are the most efficacious for
relief from fluid congestion,2 thus becoming the most fre-
quently prescribed drug class3 despite the limited evidence
to guide their prescription and titration. The use of inappro-
priately low doses of diuretics may lead to persistent edema,
whereas high doses may result in volume contraction, which
can increase the risk of hypotension and renal insufficiency.4
According to guidelines, the aim of using diuretics is to
achieve and maintain a euvolemic state and patients’ well-
being with the lowest achievable dose.5 This requires individual
diuretic dose adjustments given the progressive character of
HF, its concomitant conditions and treatments, and changes
in dietary sodium and fluid intake over time. In this study,
we assess the association of the fluctuating dose of furose-
mide with all-cause mortality over 5 years in ambulatory
patients within a wide spectrum of HF presentation.
Methods
For this retrospective cohort study, we screened 765 con-
secutive ambulatory patients referred between January 2000
and July 2011 to the HF clinic at Hospital São João in Porto,
Portugal. Inclusion criteria of HF diagnosis5 and reduced ejec-
tion fraction (≤50%) were confirmed in 632 patients; those
with uncorrected primary valvular disease (n = 10), on di-
alysis (n = 4), and attending only 1 appointment at the clinic
(n = 58) were excluded, leaving 560 patients for analysis.
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Data on patients’ characteristics, prescribed therapy, and
laboratory parameters were abstracted from records of each
clinical appointment during the study period, correspond-
ing to 4978 observations. Dynamic diuretic exposure was
determined based on furosemide dose prescribed at each
medical visit. After consultation with cardiologists special-
ized in HF, the daily dose was categorized as low (0–
59 mg), medium (60–119 mg), high (120–159 mg), and very
high doses (≥160 mg). Qualitative assessment of left ven-
tricular ejection fraction was considered as documented in
clinical records. N-terminal prohormone of brain natriuretic
peptide (BNP) values were converted into BNP6 and serum
sodium ≤133 mEq/L was defined as moderate or severe
hyponatremia.7
Patients were followed until July 31, 2012, for the end-
point of all-cause mortality. Vital status was ascertained using
the clinic’s records and telephone contacts. Patients were cen-
sored if regular hemodialysis was instituted, there was no
appointment at the clinic for more than 15 months, or after
5 years after referral, whichever came first. The study was
approved by the institutional ethics committee.
Statistical Analysis
Baseline dose categories were compared using the χ2 test
for discrete and 1-way analysis of variance or Kruskal-
Wallis tests for continuous variables. Survival was estimated
using the Kaplan-Meier method. Forty-five percent of ob-
servations had no data on at least 1 laboratory parameter, to
a large extent representing no need for tests in stable pa-
tients. Data on variables other than laboratory parameters were
lacking in 6% of observations. Absent and missing data, as
well as nonexistent BNP values (N-terminal prohormone of
BNP/BNP blood test became available at the hospital after
2003) were handled by multiple imputation using mixed effects
multivariable regression models. Extended Cox models were
used to assess the association between dynamic diuretic dose
and all-cause mortality. The dynamic dose was sequentially
adjusted for the baseline dose (Table 1, model 2), time-
independent confounders (age, sex, ischemic etiology, diabetes
mellitus, and atrial fibrillation) (model 3), time-varying disease
severity indicators (hospital admissions resulting from HF,
New York Heart Association [NYHA] class, and BNP) (model
4), time-varying laboratory and physiologic parameters (cre-
atinine, sodium, and systolic blood pressure), (model 5) and
concomitant disease-modifying treatments (angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers,
and β-blockers) (model 6).
Sensitivity analyses were performed to examine the effect
of increased dose of furosemide on 2-year survival. Statis-
tical analyses were performed using Stata and R softwares.
P values <.05 were considered significant.
Results
Overall characteristics at referral included median age of 70
years, 67% male, 46% of ischemic etiology, 89% with moderate-
severely reduced EF, and 62% in NYHA class II (Table 2).
Higher referral daily diuretic doses were related with clin-
ical markers of more severe disease, including higher NYHA
class, higher BNP and serum creatinine, lower systolic blood
pressure, and lower hemoglobin levels. Patients on higher daily
diuretic doses were more often hospitalized for HF in the pre-
ceding year and more frequently had comorbidities. Over 6
months and 5 years of follow-up, 85% and 40% of patients
remained in the same diuretic dose category as at baseline,
respectively (Fig. 1).There were 109 deaths during the follow-
up period, with increasing 5-year risk of death across referral
diuretic dose categories (26%, 32%, 43%, and 56% in low,
medium, high, and very high dose groups, respectively; log-
rank test: P < .001).
In univariable analysis of dynamic dose (Table 1, model
1) a higher furosemide dose was associated with a progres-
sively higher mortality. When adjusted for baseline dose (model
2) and other time-independent confounders (model 3), very
high dose was independently related with higher risk of death;
however, this association became close to null after control-
ling for HF severity (model 4). Subsequent adjustment for
serum creatinine, systolic blood pressure, and hyponatre-
mia (model 5), and additionally for prognosis-modifying
therapy (model 6), had no impact on the association between
diuretic dose and risk of death.
In sensitivity analysis, high furosemide dose prescribed at
referral was associated with higher 2-year mortality, whereas
Table 1. Hazard ratio for mortality according to time-varying diuretic dose categories over 5 years, adjusted for the baseline dose and
multiple confounders
Model Low Medium High Very High Variables Included
1 1* 1.38 (1.00–1.89) 1.51 (1.06–2.16)† 2.09 (1.54–2.84)† Time-varying diuretic dose
2 1* 1.28 (0.93–1.77) 1.34 (0.93–1.93) 1.85 (1.36–2.53)† Baseline diuretic dose + time-varying diuretic dose
3 1* 1.18 (0.86–1.61) 1.22 (0.85–1.76) 1.63 (1.19–2.22)† Model 2 + age + sex + ischemic etiology + atrial fibrillation + diabetes
mellitus (baseline)
4 1* 1.06 (0.76–1.45) 0.94 (0.65–1.37) 1.06 (0.76–1.47) Model 3 + NYHA class + BNP + HF hospitalization (baseline and
time-varying)
5 1* 1.08 (0.78–1.49) 0.97 (0.66–1.43) 1.12 (0.80–1.57) Model 4 + serum creatinine + blood pressure + hyponatremia (baseline and
time-varying)
6 1* 1.11 (0.80–1.54) 0.94 (0.63–1.38) 1.10 (0.79–1.55) Model 5 + ACE inhibitor + β-blocker treatment (baseline and time-varying)
N = 560 patients; 4978 observations; absent data in each observation (missing or no laboratory tests ordered) were imputed.
*Reference class.
†P < .05 vs. low dose.
590 Journal of Cardiac Failure Vol. 23 No. 8 August 2017
Table 2. Patient Characteristics at Baseline
All Low Dose Medium Dose High Dose Very High Dose Pvalue
No. of patients 560 164 252 93 51
Age (y), median (IQR) 70.0 (57.3–78.7) 65.8 (53.7–76.5) 70.1 (57.1–79.2) 74.1 (63.5–79.7) 70.2 (61.5–77.0) .015
Male sex, % 67.0 69.5 64.7 68.8 66.7 .748
Ischemic etiology, % 46.1 45.1 46.8 40.9 54.9 .434
Diabetes mellitus, % 35.5 32.3 34.1 37.6 49.0 .159
Hypertension, % 61.6 58.5 62.7 61.3 66.8 .720
Arial fibrillation, % 37.7 24.4 40.9 48.4 45.1 <.001
Chronic kidney disease, % 45.7 32.9 48.0 46.2 74.5 <.001
Hospitalization for HF in previous year, % 45.5 29.3 50.0 52.7 62.6 <.001
Ejection fraction (%), median (IQR)* 26 (20–35) 28 (21–35) 27 (20–35) 25 (21–33) 25 (20–30) .304
Moderate-severe reduced EF, % 88.9 88.4 88.5 88.2 94.1 .673
NYHA class, % I 18.7 29.2 18.5 8.0 6.0
II 62.0 57.8 65.4 59.8 62.0
III 18.0 13.0 15.2 28.7 28.0
IV 1.3 0.0 0.9 3.5 4.9 <.001
Systolic blood pressure (mmHg), mean (SD) 120.4 (24.3) 124.1 (24.6) 119.9 (24.7) 120.7 (23.8) 110.8 (20.1) .012
Heart rate (beats/min), mean (SD) 78.3 (13.9) 78.5 (12.5) 78.1 (14.5) 78.6 (14.1) 78.1 (15.7) .985
BNP (pg/mL), median (IQR) 458.5 (224.8–1047.0) 193.4 (93.8–454.2) 530.5 (263.1–995.8) 569.1 (306.7–1441.4) 1281.0 (508.1–2918.5) <.001
Creatinine (mg/dL), median (IQR) 1.1 (0.9–1.4) 1.0 (0.9–1.3) 1.1 (1.0–1.4) 1.1 (0.9–1.5) 1.4 (1.0–2.0) <.001
Uric acid (mg/L), median (IQR) 74.9 (62.7–89.2) 67.0 (56.4–79.2) 76.6 (64.8–90.8) 77.7 (63.4–93.9) 88.4 (70.3–110.5) <.001
Hyponatremia, % 6.7 6.2 5.2 6.2 15.7 .057
Hemoglobin (g/dL), mean (SD) 13.2 (1.9) 13.5 (1.9) 13.2 (1.9) 12.8 (1.9) 12.5 (2.0) .009
Diuretic dose (mg/day), median (IQR) 80 (40–120) 40 (20–40) 80 (80-80) 120 (120-120) 160 (160-160) <.001
Metolazone, % 2.3 0.0 1.2 4.3 11.8 <.001
ACE inhibitors, % 89.8 92.1 88.9 89.3 88.2 .724
β-blocker, %† 75.4 74.4 78.6 65.6 80.4 .073
Spironolactone, % 32.5 19.5 36.1 41.0 41.2 <.001
Follow-up (months), median (IQR) 23 (9–44) 26 (10–48) 22 (10–41) 19 (8–40) 16 (6–51) .192
Time between appointments (days), median (IQR) 79 (41–123) 94 (54–153) 83 (41–118) 62 (34–104) 62 (34–97) <.001
No of visits/patient 8 (4–12) 8 (4–11) 8 (4–13) 7 (3–13) 8 (3–15) .848
ACE, angiotensin–converting enzyme; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; HF, heart failure; IQR, interquartile range; MI, myocardial infarction;
NYHA, New York Heart Association; SD, standard deviation.
*Data available for 264 patients.
†Carvedilol, bisoprolol, or nebivolol.
Prognostic
Effect
ofLoop
D
iuretic
D
ose
•
Laszczyn´
ska
et
al
591
time-varying dose showed no effect on risk of death Appendix
S1, (Supplementary Table A, model 6).
Discussion
Higher doses of furosemide were strongly associated with
subsequent death, with a clear dose-dependent increase in crude
risk. However, the association was totally explained by pa-
tients’ characteristics and confounders reflecting the severity
of the patient’s condition and greater comorbidities.
Our conclusion that diuretics dose may be more a marker
than a cause of instability is consistent with previous reports.3,8
At the same time, high diuretic doses were associated with
increased rehospitalizations and mortality.9 Evaluation of the
prognostic effect of diuretic in chronic therapy based on single
baseline dose only may be a simplification, especially for long-
term perspective. Currently, there is no specific strategy for
diuretic treatment in HF, and recommendations are for the
minimum dose to allow maintenance of the euvolemic state.5
This may require a process of frequent reappraisal of diuret-
ic regimen in the face of changes in disease status, concomitant
medication, and dietary sodium and fluid intake. Adjust-
ment of diuretic dosing according to fluid overload has been
related with more favorable prognosis.10,11 In our clinic, fu-
rosemide dose is determined during each appointment in
respect to the actual volume status (presence of edema, rales,
orthopnea, weight control, jugular venous pressure) and overall
clinical condition (NYHA class, laboratory test), assuring that
the prescribed therapy responds to the individual’s demands.
The need for dynamic furosemide dose analysis was reaf-
firmed by the frequent dose readjustments; one-half of patients
altered diuretic dose within 1 year after referral, more often
toward higher doses.12 Despite widespread support for ti-
trated diuretic dose in HF management, prognostic implication
of time-varying diuretic dosage has not been thoroughly in-
vestigated. Abdel-Qadir et al13 suggested that exposure to
higher furosemide dose was associated with increased risk
of hospital readmission and death; however, the effect of the
dynamic dose was controlled for baseline covariates only. In
our study, after multiple adjustments for time-varying factors
and the risk of death were not significantly different between
patients treated with low and high doses.
In a sensitivity analysis, we demonstrated that, in the
medium term, the baseline diuretic dose carries a distinct prog-
nostic value, explaining at least in part the strong association
reported previously for shorter follow-up.14,15 However, in the
longer perspective, its importance decreased in favor of the
time-varying dose (Appendix S1, Supplementary Table B,
model 6).
The study provided detailed information on outpatient di-
uretic exposure over time and extensive characterization of
disease severity and other potential confounders for inclu-
sion in the time-dependent analysis in a relatively large sample
of patients.
We did not consider in-hospital and postdischarge diuret-
ic doses as well as possible influence of the patient’s adherence
to medications on mortality. In our clinic, furosemide is the
only loop diuretic prescribed to chronic patients; a possible
short course of metolazone translates into a negligible ex-
posure time. The group of 58 excluded patients was not
significantly different from the participants in baseline char-
acteristics; therefore, a putative selection bias is expectedly
small. The use of medical records of routine care contrib-
utes to the pragmatic generalizability of the results; however,
findings of this single-center study may not be extrapolated
to different settings.
In conclusion, ambulatory HF patients experienced fre-
quent furosemide dose adjustment, usually toward higher
doses. Intensity of diuretic treatment seems to reflect the se-
verity of patient’s condition, and its chronic use had no
independent effect on 5-year survival. Our results confirm that
aggressive diuretic therapy may be safe if adequately tai-
lored for congestion status.
Fig. 1. Diuretic dose categories distribution over 5 years accord-
ing to furosemide dose at baseline.
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